Top Analytics Companies in Bengaluru (111)

Market Expansion: The merger with Accolite in 2024, global rebrand in 2025, and the 2026 Cartesian acquisition broadened footprint across North America, Europe, and India. Leadership appointments to run the India practice indicate continued investment in global delivery capacity.

Innovation-Driven Growth: The Cartesian deal was positioned to accelerate enterprise AI capabilities, and joining Anthropic’s Claude Partner Network signals an AI-led services push. Feedback suggests these moves deepen data and analytics strengths rather than retrenchment.

Strategic Partnerships: Recent partner accolades such as Acquia’s 2024 North America Partner of the Year and broader ecosystem momentum point to healthy demand and platform depth. Alliances highlighted across AI and digital experience stacks support go-to-market expansion.

Strong Revenue Growth: Revenue scale is signaled by surpassing $500M in annual recurring revenue in July 2023, creating a high base for subsequent expansion. Company communications frame later moves as building on this milestone.

Market Expansion: Recent acquisitions—Spatial Business Systems, PDS Energy’s exchange platforms, and TGS’s A2D well log library—extend reach into utilities engineering, operational exchanges, and subsurface data. Solutions marketed across upstream, midstream, power and renewables point to a broadening footprint.

Investor Backing & Capital Strength: Blackstone agreed in August 2025 to acquire Enverus in a deal reported at $6.5B+ and later referenced deploying capital into the company in 1Q26. This indicates substantial resources and conviction to support further scaling.

Strong Revenue Growth: Revenue is accelerating with multiple raised full‑year outlooks and consecutive quarters of rapid top‑line increases. The business also highlights a long “beat and raise” cadence into 2026.

Profitability: GAAP net income turned positive in 2026 alongside expanding adjusted EBITDA. Management continues to guide to improved margins through the year.

Healthy Cash Flow: Free cash flow is rising and full‑year cash generation guidance was increased. Disclosures point to stronger operating cash flow through the first half of 2026.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Strong Revenue Growth: Company communications describe ARR more than tripling in 2025, marking its strongest year to date. These disclosures point to clear top‑line momentum into 2026.

Product Line Growth: Announcements highlight expanded AI functionality for healthcare in June 2026 alongside ongoing platform updates. This indicates continued investment in new capabilities and vertical depth.

Strong Hiring & Retention: Multiple senior appointments in mid‑2026, including an EVP of Technology & Operations and additional leadership roles, suggest active scaling of the executive and technical bench. References to broader team expansion reinforce organizational build‑out.

Strong Market Position & Advantage: Independent market-share analysis places Celonis at the front of its category while the market itself expands. This positioning suggests the company is capturing growth in a segment it leads.

Future-Ready Strategy: External recognition for long-term growth potential signals confidence in Celonis’s strategy, innovation, and talent pipeline. This points to preparedness as the space broadens from process mining into process intelligence and AI-enabled workflows.

Strategic Partnerships: A new alliance with a major data and AI platform provider expands product integrations and go-to-market reach into enterprise AI workflows. Such ecosystem momentum supports broader adoption and commercial expansion.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.

Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.

Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.

Strong Market Position & Advantage: Independent analyst leadership and a large installed base signal a durable competitive position in P&C core platforms, reinforced by recognition from Gartner, Forrester, and Celent. A broad partner ecosystem and marketplace integrations further strengthen adoption and delivery at scale.

Strong Revenue Growth: Recent quarters and fiscal-year results indicate robust, double‑digit top‑line expansion, with subscription and support growing faster than overall revenue. Raised guidance and expanding remaining performance obligations support continued momentum.

Profitability: Earnings metrics improved meaningfully year over year, reflecting operating leverage as cloud revenue scales. Management highlighted stronger operating cash generation alongside growth in higher‑margin subscription revenue.

Strong Market Position & Advantage: ABB is positioned as a top-tier or No. 1 player across several core categories, including drives and motors, distributed control systems (DCS), and key electrification/switchgear segments, supporting defensible leadership in retained businesses.

Strong Revenue Growth: ABB’s 2025 results show clear expansion in orders and revenue alongside a record backlog, which increases near-term visibility and supports continued growth expectations into 2026.

Profitability: Margin expansion and strong operational EBITA performance, alongside improved gross margin and higher cash generation, indicate disciplined execution translating scale and demand into resilient profitability.